🇩🇪Germany

Marktrückzüge durch Preisdruck und Compliance-Barrieren

3 verified sources

Definition

Pricing pressures from 2022 FinStG and MFG have caused withdrawals; high dev costs exacerbate non-compliance risks.

Key Findings

  • Financial Impact: €1.2bn+ development sunk per unlaunched product; €54bn total pharma spend with 6.6% on patents under pressure
  • Frequency: Per failed market entry decision
  • Root Cause: Poor data on local trial ROI and penalty forecasts

Why This Matters

This pain point represents a significant opportunity for B2B solutions targeting Biotechnology Research.

Affected Stakeholders

CEO, Market Access Director, CFO

Deep Analysis (Premium)

Financial Impact

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Current Workarounds

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Get Solutions for This Problem

Full report with actionable solutions

$99$39
  • Solutions for this specific pain
  • Solutions for all 15 industry pains
  • Where to find first clients
  • Pricing & launch costs
Get Solutions Report

Methodology & Sources

Data collected via OSINT from regulatory filings, industry audits, and verified case studies.

Evidence Sources:

Related Business Risks

Request Deep Analysis

🇩🇪 Be first to access this market's intelligence